<?xml version="1.0" encoding="UTF-8"?>
<collection>
<dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:invenio="http://invenio-software.org/elements/1.0" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:identifier>doi:10.1089/tmj.2018.0264</dc:identifier><dc:language>eng</dc:language><dc:creator>Echarri, A</dc:creator><dc:creator>Vera, I</dc:creator><dc:creator>Ollero, V</dc:creator><dc:creator>Arajol, C</dc:creator><dc:creator>Riestra, S</dc:creator><dc:creator>Robledo, P</dc:creator><dc:creator>Calvo, M</dc:creator><dc:creator>Gallego, F</dc:creator><dc:creator>Ceballos, D</dc:creator><dc:creator>Castro, B</dc:creator><dc:creator>Aguas, M</dc:creator><dc:creator>García-López, Santiago</dc:creator><dc:creator>Mar?n-Jim?nez, I</dc:creator><dc:creator>Chaparro, M</dc:creator><dc:creator>Mesonero, P</dc:creator><dc:creator>Guerra, I</dc:creator><dc:creator>Guardiola, J</dc:creator><dc:creator>Nos, P</dc:creator><dc:creator>Mu?iz, J</dc:creator><dc:title>The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study</dc:title><dc:identifier>ART-2020-116426</dc:identifier><dc:description>Objectives: Mobile apps are useful tools in e-health and self-management strategies in disease monitoring. We evaluated the Harvey-Bradshaw index (HBI) mobile app self-administered by the patient to see if its results agreed with HBI in-clinic assessed by a physician. 

Methods: Patients were enrolled in a 4-month prospective study with clinical assessments at months 1 and 4. Patients completed mobile app HBI and within 48 h, HBI was performed by a physician (gold standard). HBI scores characterized Crohn''s disease (CD) as remission &lt;5 or active &gt;= 5. We determined agreement per item and total HBI score and intraclass correlation coefficients (ICCs). Bland-Altman plot was performed. HBI changes in disease activity from month 1 to month 4 were determined. Results: A total of 219 patients were enrolled. All scheduled assessments (385 pairs of the HBI questionnaire) showed a high percentage of agreement for remission/activity (92.4%, kappa = 0.796), positive predictive value (PPV) for remission of 98.2%, and negative predictive value of 76.7%. High agreement was also found at month 1 (93.15%, kappa = 0.82) and month 4 (91.5%, kappa = 0.75). Bland-Altman plot was more uniform when the HBI mean values were &lt;5 (remission). ICC values were 0.82, 0.897, and 0.879 in all scheduled assessments, 1 and 4 months, respectively. 

Conclusions: We found a high percentage of agreement between patients' self-administered mobile app HBI and in-clinic physician assessment to detect CD activity with a remarkably high PPV for remission. The mobile app HBI might allow a strict control of inflammation by remote monitoring and flexible follow-up of CD patients. Reduction of sanitary costs could be possible.</dc:description><dc:date>2020</dc:date><dc:source>http://zaguan.unizar.es/record/95857</dc:source><dc:doi>10.1089/tmj.2018.0264</dc:doi><dc:identifier>http://zaguan.unizar.es/record/95857</dc:identifier><dc:identifier>oai:zaguan.unizar.es:95857</dc:identifier><dc:relation>info:eu-repo/grantAgreement/ES/ISCIII/FIS/2015–2017</dc:relation><dc:identifier.citation>TELEMEDICINE AND E-HEALTH 26, 1 (2020), 78-86</dc:identifier.citation><dc:rights>by</dc:rights><dc:rights>http://creativecommons.org/licenses/by/3.0/es/</dc:rights><dc:rights>info:eu-repo/semantics/openAccess</dc:rights></dc:dc>

</collection>